Market Reports Center One Stop Market Reaserch Shop Global Urological Cancer Market Size, Share, Global Insights, Analysis and Outlook, Emerging Trends and Research Report by Market Reports Center Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics Global Urological Cancers Market Will Double to $35.9 billion by 2022, says GBI Research The urological cancers market, including bladder, kidney, prostate and testicular cancer, will increase from $17.9 billion in 2015 to $35.9 billion by 2022, at a substantial compound annual growth rate of 10.39%, according to business intelligence provider GBI Research. The companys latest report* states that this strong market growth will be driven by the predicted emergence of targeted therapies for bladder cancer and increasing prostate and kidney cancer prevalence. Adam Bradbury, Analyst for GBI Research, explains: “ The development and approval of immune checkpoint inhibitors will lower the associated toxicity of urological cancer therapies and increase their usage in typically poor-performance patients, who have a reduced functional status. Targeted treatment administration will increase patients’ overall survival and enable more rounds of chemotherapy to be given. Browse full report with TOC@ https://marketreportscenter.com/reports/330416/global-urologicalcancer-market-to-2022-strong-growth-driven-by-rising-prevalence-increased-uptake-of-hormonetherapies-and-approval-of-novel-biologics It is predicted that two new urological cancer drugs for the treatment of bladder cancer – Roche’ s atezolizumab and AstraZenecas durvalumab – will achieve blockbuster status by 2022. The former is anticipated to achieve revenue of $2.5 billion in 2022, following approval from late 2016, and its uptake will be driven by a lack of targeted therapies for bladder cancer, along with increasing prevalence and clinician familiarity. Market Reports Center One Stop Market Reaserch Shop The latter is anticipated to generate $1.2 billion in 2022, following its expected approval in 2017. It is expected to be one of an increasing number of cancer immunotherapies for bladder cancer, providing less toxic options for treatment of the malignancy, and enabling administration to patients with poorer performance statuses. Although drugs such as atezolizumab and durvalumab are not expected to surpass the revenues generated by the currently marketed drugs Opdivo or Xtandi due to a competitive market landscape, their approval and uptake will cause shifts in market dynamics. As Bradbury continues: “ Key players Johnson & Johnson and Pfizer, for example, are predicted to have decreasing market shares due to decreasing or static drug revenues as the overall market revenues rise. Those of Roche and Bristol-Myers Squibb (BMS), on the other hand, will increase due to the uptake of recently approved and upcoming immune checkpoint inhibitors such as atezolizumab, and BMS’ s Opdivo and Yervoy. Astellas is forecast to maintain its strong market share through to 2022 due to increasing Xtandi revenues. *Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics This report provides analysis of the global urological cancer space across the seven major countries of the US, France, Germany, Italy, Spain, the UK, and Japan. It includes annualized market data from 2015 and forecast to 2022. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’ s team of industry experts. Summary Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular and bladder cancer – the key indications covered in this report – accounting for the majority of that figure. Urological cancers affect the male and female urinary tract and the male reproductive organs. Prostate cancer is the most prevalent of these malignancies. A number of common etiologic factors have been strongly characterized as raising the risk of developing urological cancers, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments. Hormone therapies for prostate cancers and angiogenesis inhibitors for renal cell carcinoma are currently the most commercially successful urological cancer drugs. However, there has been a shift towards the clinical testing of cancer immunotherapies – such as Opdivo, which was recently approved for renal cell carcinoma. The forecast period will also witness the approval of a greater number of targeted therapies, which by their nature have less toxicity associated with their use, and as a result can be administered to patients with poor performance statuses, therefore increasing the overall survival of this group and the number of treatment cycles they may receive. Request A Sample copy of This Report @ https://marketreportscenter.com/request-sample/330416 Market Reports Center One Stop Market Reaserch Shop Scope - Global revenues for the urological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.39%, from $17.9 billion in 2015 to $35.9 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period? - The urologic oncology pipeline is large and diverse, and contains 817 products. How does the composition of the pipeline compare with that of the existing market? - What mechanisms of action and molecule types are most common for pipeline drugs being trialed in the various key indications? - How will the market shares and CAGRs of the top 20 companies compare within this therapy area? - What proportion of the key players’ revenues will be attributable to urological cancers? Reasons to buy This report will allow you to – - Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis - Visualize the composition of the urological cancer market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players - Analyze the urological cancer pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications - Understand the growth in patient epidemiology and market revenues for the urological cancer market globally and across the key players and product types - Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various urological cancers - Identify commercial opportunities in the urological cancer deals landscape by analyzing trends in licensing and co-development deals To Get Discount On The Report @ https://marketreportscenter.com/request-discount/330416 Connect for more details: Sam Collins Market Reports Center 1-646-883-3044 (US) [email protected]
The urological cancers market, including bladder, kidney, prostate and testicular cancer, will increase from $17.9 billion in 2015 to $35.9 billion by 2022
© Copyright 2024 Paperzz
